Mylan
2
16M
2
0.03
2
1
- Areas of investment
Summary
Mylan is the famous Corporate Investor, which was founded in 1961. The main office of represented Corporate Investor is situated in the Canonsburg. The venture was found in North America in United States.
We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight ZYOMYX. Besides, a startup needs to be aged 11-15 years to get the investment from the fund.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2013. The fund is constantly included in less than 2 deals per year.
The usual cause for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Jenny Rooke, Bill & Melinda Gates Foundation.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 2
- Exits
- 1
- Rounds per year
- 0.03
- Investments by industry
- Biotechnology (2)
- Pharmaceutical (2)
- Health Diagnostics (1)
- Health Care (1)
- Investments by region
-
- Israel (1)
- United States (1)
- Peak activity year
- 2013
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Group Appearance index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ZYOMYX | 30 Jun 2013 | Biotechnology, Health Diagnostics, Pharmaceutical | Early Stage Venture | 12M | United States, Missouri |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.